Sun Pharma Acquisition

Aquinox Pharmaceuticals is a research and development company focused on pharmaceutical products for the purpose of their commercialisation, Sun Pharma said.

Top gainers on the 50-scrip Nifty index included Reliance Industries, Cipla, Coal India, Sun Pharma and Lupin. The Nifty Pharma rose 2.7% led by Aurobindo Pharma, which surged over 9% after the drug maker announced a $900-million acquisition in the US.

Sun gained the plant along with its acquisition of Ranbaxy Laboratories in 2015 and has been attempting to fix quality control problems there that the US Food and Drug Administration (FDA) identified in 2013.

This transaction gives the company access to local manufacturing capability across multiple dosage forms in Russia,

Currently, Ocular is developing Seciera for treating dry eye disease, the city-based company said, adding the drug is currently in Phase-3 confirmatory clinical trials.

New Delhi: In line with global trends in thepharmaceuticals sector, the focus of domestic drug firms on acquisitionsto consolidate their position will limit deleveraging for thetime being, rating agency Fitch has said. "The ongoing focus of the top Indian pharma companies' onselective acquisitions to limit deleveraging over the shortterm," Fitch...

Keen on inorganic expansion, Sun Pharma has said it is looking for targets that are "well managed" unlike the acquisition of Ranbaxy which continues to take significant time of the senior management.

The company however did not share financial details. The US-based firm has also agreed to offer employment to all production, quality and administrative personnel at the sites.

Competition Commission has approved multiplex chain PVR's proposed acquisition of DT Cinemas from DLF while directing the companies to exclude certain assets from the deal to address anti-competitive concerns.

Drug major Sun Pharmaceutical Industries on Tuesday said it has completed acquisition of US-based eye care firm InSite Vision.

Sun Pharmaceutical Industries on Wednesday said its arm Thea Acquisition Corp plans to exercise a 'top-up' option to purchase shares directly from eyecare firm InSite Vision to hold a 90 per cent stake in the US-based company to complete a merger, after failing to get the required number of shares through a tender offer.

Shareholders of the company, at the 22nd AGM on September 27, 2014 had already approved the resolution to earmark Rs 50,000 crore.

The company "has commenced a tender offer through its indirect wholly owned subsidiary, Thea Acquisition Corporation, for all of the outstanding shares of common stock of InSite Vision Incorporated for $0.35 per share in cash, without interest and less any required withholding taxes," Sun Pharma said in a statement.

Sun Pharma decided to make the open offer after its acquisition of Ranbaxy, which had held significant stake in Zenotech.

Fresh from its $4-billion takeover of Ranbaxy, Sun Pharmaceutical Industries says it is open to further acquisitions but will consider only targets "which will not require significant amount of management involvement".

Aquinox Pharmaceuticals is a research and development company focused on pharmaceutical products for the purpose of their commercialisation, Sun Pharma said.

Top gainers on the 50-scrip Nifty index included Reliance Industries, Cipla, Coal India, Sun Pharma and Lupin. The Nifty Pharma rose 2.7% led by Aurobindo Pharma, which surged over 9% after the drug maker announced a $900-million acquisition in the US.

Sun gained the plant along with its acquisition of Ranbaxy Laboratories in 2015 and has been attempting to fix quality control problems there that the US Food and Drug Administration (FDA) identified in 2013.

This transaction gives the company access to local manufacturing capability across multiple dosage forms in Russia,

Currently, Ocular is developing Seciera for treating dry eye disease, the city-based company said, adding the drug is currently in Phase-3 confirmatory clinical trials.

New Delhi: In line with global trends in thepharmaceuticals sector, the focus of domestic drug firms on acquisitionsto consolidate their position will limit deleveraging for thetime being, rating agency Fitch has said. "The ongoing focus of the top Indian pharma companies' onselective acquisitions to limit deleveraging over the shortterm," Fitch...

Keen on inorganic expansion, Sun Pharma has said it is looking for targets that are "well managed" unlike the acquisition of Ranbaxy which continues to take significant time of the senior management.

The company however did not share financial details. The US-based firm has also agreed to offer employment to all production, quality and administrative personnel at the sites.

Competition Commission has approved multiplex chain PVR's proposed acquisition of DT Cinemas from DLF while directing the companies to exclude certain assets from the deal to address anti-competitive concerns.

Drug major Sun Pharmaceutical Industries on Tuesday said it has completed acquisition of US-based eye care firm InSite Vision.

Sun Pharmaceutical Industries on Wednesday said its arm Thea Acquisition Corp plans to exercise a 'top-up' option to purchase shares directly from eyecare firm InSite Vision to hold a 90 per cent stake in the US-based company to complete a merger, after failing to get the required number of shares through a tender offer.

Shareholders of the company, at the 22nd AGM on September 27, 2014 had already approved the resolution to earmark Rs 50,000 crore.

The company "has commenced a tender offer through its indirect wholly owned subsidiary, Thea Acquisition Corporation, for all of the outstanding shares of common stock of InSite Vision Incorporated for $0.35 per share in cash, without interest and less any required withholding taxes," Sun Pharma said in a statement.

Sun Pharma decided to make the open offer after its acquisition of Ranbaxy, which had held significant stake in Zenotech.

Fresh from its $4-billion takeover of Ranbaxy, Sun Pharmaceutical Industries says it is open to further acquisitions but will consider only targets "which will not require significant amount of management involvement".